Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

2006 ◽  
Vol 28 (4) ◽  
pp. 351-364 ◽  
Author(s):  
Thomas F. Tedder ◽  
Aris Baras ◽  
Yan Xiu
Keyword(s):  
B Lymphocyte ◽  
Fcγ Receptor ◽  
Cd20 Antibody ◽  
Effector Mechanisms

scholarly journals Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

2008 ◽  
Vol 2008 ◽  
pp. 1-6 ◽  
Author(s):  
D. T. Klink ◽  
R. M. van Elburg ◽  
M. W. J. Schreurs ◽  
G. T. J. van Well
Keyword(s):  
B Lymphocytes ◽  
Growth And Development ◽  
B Lymphocyte ◽  
Normal Growth ◽  
B Cell Development ◽  
Third Trimester ◽  
B Lymphocyte Development ◽  
Cd20 Antibody ◽  
Anti Cd20 ◽  
Fetus And Neonate

We describe the effect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura (ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy. One month after the last rituximab administration a healthy girl was born. She had normal growth and development during the first six months. At birth, B-lymphocytes were not detectable. Rituximab levels in mother and neonate were 24000 and 6700 ng/mL, respectively. Only 7 cases of rituximab administration during pregnancy were described. No adverse events are described for fetus and neonate. We demonstrate that rituximab passes the placenta and inhibits neonatal B-lymphocyte development. However, after 6 months B-lymphocyte levels normalized and vaccination titres after 10 months were adequate. No infection-related complications occurred. Rituximab administration during pregnancy appears to be safe for the child but further studies are warranted.

scholarly journals The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option

2006 ◽  
Vol 154 (5) ◽  
pp. 623-632 ◽  
Author(s):  
Daniel El Fassi ◽  
Claus H Nielsen ◽  
Hans C Hasselbalch ◽  
Laszlo Hegedüs
Keyword(s):  
B Cell ◽  
Treatment Option ◽  
B Lymphocyte ◽  
Thyroid Autoimmunity ◽  
Antibody Therapy ◽  
Graves Disease ◽  
Novel Treatment ◽  
Thyroid Associated Ophthalmopathy ◽  
Cd20 Antibody ◽  
Anti Cd20

We have reviewed the immunology of thyroid autoimmunity with special reference to the importance of B lymphocytes (B cells) in thyroidal and extrathyroidal Graves’ disease (GD), thus providing a framework for the hypothesis that B cell depletion may be beneficial in GD. Additionally, after reviewing the efficacy and safety in other autoimmune diseases, we propose that treatment with the B cell-depleting agent Rituximab may become a clinically relevant treatment option in selected cases of GD, particularly when complicated with thyroid-associated ophthalmopathy.

scholarly journals Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study

PLoS ONE ◽  
2011 ◽  
Vol 6 (10) ◽  
pp. e26358 ◽  
Author(s):  
Øystein Fluge ◽  
Ove Bruland ◽  
Kristin Risa ◽  
Anette Storstein ◽  
Einar K. Kristoffersen ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
B Lymphocyte ◽  
Chronic Fatigue ◽  
Controlled Study ◽  
Double Blind ◽  
Lymphocyte Depletion ◽  
Fatigue Syndrome ◽  
Cd20 Antibody ◽  
Anti Cd20

scholarly journals Anti-CD20 Antibody Therapy and Susceptibility to Pneumocystis Pneumonia

2015 ◽  
Vol 83 (5) ◽  
pp. 2043-2052 ◽  
Author(s):  
Waleed Elsegeiny ◽  
Taylor Eddens ◽  
Kong Chen ◽  
Jay K. Kolls
Keyword(s):  
B Lymphocyte ◽  
Developmental Stages ◽  
Case Reports ◽  
Antibody Therapy ◽  
Pneumocystis Pneumonia ◽  
Interleukin 4 ◽  
Content Type ◽  
Cd20 Antibody ◽  
Anti Cd20

Anti-CD20 antibody therapy has been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases characterized by autoantibody generation. CD20 is expressed during most developmental stages of B lymphocytes; thus, CD20 depletion leads to B-lymphocyte deficiency. As the drug has become more widely used, there has been an increase in the number of case reports of patients developingPneumocystispneumonia. The role of anti-CD20 inPneumocystis jiroveciiinfection is under debate due to the fact that most patients receiving it are on a regimen of multiple immunosuppressive medications. To address the specific role of CD20 depletion in host immunity againstPneumocystis, we examined a murine anti-CD20 depleting antibody. We demonstrated that anti-CD20 alone is permissive forPneumocystisinfection and that anti-CD20 impairs components of type II immunity, such as production of interleukin-4 (IL-4), IL-5, and IL-13 by whole-lung cells, in response toPneumocystis murina. We also demonstrated that CD4+T cells from mice treated with anti-CD20 duringPneumocystisinfection are incapable of mounting a protective immune response when transferred into Rag1−/−mice. Thus, CD20+cells are critical for generating protective CD4+T-cell immune responses against this organism.

Functional interaction of calmodulin with the Fcγ-receptor FcRn

2001 ◽  
Vol 120 (5) ◽  
pp. A698-A698
Author(s):  
B DICKINSON ◽  
S CLAYPOOL ◽  
R BLUMBERG ◽  
W LENCER
Keyword(s):  
Fcγ Receptor ◽  
Functional Interaction

Novel treatment opportunities in Graves’ orbitopathy

2014 ◽  
Vol 155 (33) ◽  
pp. 1295-1300
Author(s):  
Annamária Erdei ◽  
Annamária Gazdag ◽  
Miklós Bodor ◽  
Eszter Berta ◽  
Mónika Katkó ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Clinical Course ◽  
Treatment Protocol ◽  
Treatment Modalities ◽  
Graves Disease ◽  
Novel Treatment ◽  
Graves Orbitopathy ◽  
Cd20 Antibody ◽  
Anti Cd20 ◽  
Novel Therapeutic

Graves’ orbitopathy is the most common extrathyroidal manifestation of Graves’ disease. Up to now, curative treatment modalities for the most severe sight-threatening cases have not been developed. Here the authors summarize the treatment protocol of Graves’ orbitopathy and review novel therapeutic options. They review the literature on this topic and present their own clinical experience. The authors point out that anti-CD20 antibody could positively influence the clinical course of Graves’ orbitopathy. Selenium is efficient in mild cases. Further prospective investigations are warranted. Orv. Hetil., 2014, 155(33), 1295–1300.

Sign in / Sign up

Export Citation Format

Share Document